Clinical Trial Update: A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating CT1190B for relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CT1190B

Snippet

Sponsor: Aibin Liang，MD，Ph.D. | Conditions: B-Cell Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING